Moderators and Other Predictors of Methylphenidate Response in Children and Adolescents with ADHD.
ADHD
behavioral and emotional symptoms
conduct symptoms
executive functions
methylphenidate
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
31 01 2022
31 01 2022
Historique:
received:
21
12
2021
revised:
25
01
2022
accepted:
28
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Methylphenidate (MPH) is the treatment of first choice for developmental ADHD. To date, no reliable method to predict how patients will respond to MPH exists and conflicting results are reported on clinical characteristics of responders. The present study aims to give a more precise characterization of the patients who will respond best to MPH to help clinicians in defining the treatment plan. Age, neuropsychological functioning (i.e., attention and working memory), and behavioral/emotional symptoms of 48 drug-naïve children and adolescents with ADHD (42 boys and 6 girls, age-range 6-16 years, mean age 10.5 ± 2.5 years, mean IQ 101.3 ± 11.2) were studied to assess how these different characteristics affected a single-dose MPH response. Four hierarchical linear regression models were used to explore whether age, neuropsychological measures at baseline, and behavioral/emotional symptoms could predict attention and working memory measures after a single-dose MPH administration. We found that improvement in attention and working memory was predicted by age, neuropsychological measures at baseline, and severity of ADHD symptoms. No behavioral and emotional symptoms predicted single-dose MPH response with the exception of conduct symptoms.
Identifiants
pubmed: 35162663
pii: ijerph19031640
doi: 10.3390/ijerph19031640
pmc: PMC8834961
pii:
doi:
Substances chimiques
Central Nervous System Stimulants
0
Methylphenidate
207ZZ9QZ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Child Adolesc Psychopharmacol. 2021 Apr;31(3):187-196
pubmed: 33890819
Can J Psychiatry. 2010 May;55(5):305-12
pubmed: 20482957
J Neuropsychiatry Clin Neurosci. 2001 Summer;13(3):326-35
pubmed: 11514638
Biol Psychiatry. 2014 Oct 15;76(8):603-15
pubmed: 24231201
Dev Med Child Neurol. 2005 Jun;47(6):408-14
pubmed: 15934489
J Subst Abuse Treat. 2013 Feb;44(2):224-30
pubmed: 22889694
J Abnorm Child Psychol. 1998 Aug;26(4):257-68
pubmed: 9700518
Clin Pract Epidemiol Ment Health. 2019 Dec 31;15:160-171
pubmed: 32174998
Dev Neuropsychol. 2008;33(1):44-61
pubmed: 18443969
Brain Sci. 2021 Oct 24;11(11):
pubmed: 34827398
Mol Psychiatry. 2022 Jan 14;:
pubmed: 35027679
Psychol Med. 2020 Apr;50(6):894-919
pubmed: 32216846
Expert Rev Neurother. 2008 Oct;8(10):1563-71
pubmed: 18928348
Noro Psikiyatr Ars. 2019 Mar;56(1):27-31
pubmed: 30911234
Biol Psychiatry. 2007 Nov 1;62(9):954-62
pubmed: 17543895
Compr Psychiatry. 2020 Jul;100:152178
pubmed: 32386957
Biol Psychiatry. 2005 Jun 1;57(11):1224-30
pubmed: 15949992
J Child Psychol Psychiatry. 2018 Jan;59(1):57-67
pubmed: 28714075
Pediatrics. 2003 Feb;111(2):372-5
pubmed: 12563066
J Child Psychol Psychiatry. 2006 Nov;47(11):1184-94
pubmed: 17076758
J Clin Psychiatry. 2021 Jun 22;82(4):
pubmed: 34166587
PLoS One. 2015 Apr 06;10(4):e0121651
pubmed: 25844638
Eur Child Adolesc Psychiatry. 2012 Sep;21(9):477-92
pubmed: 22763750
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6769-74
pubmed: 22474392
Eur Child Adolesc Psychiatry. 2010 Apr;19(4):353-64
pubmed: 19763664
J Child Adolesc Psychopharmacol. 2013 Aug;23(6):410-4
pubmed: 23952188
Harv Rev Psychiatry. 2017 Mar/Apr;25(2):50-64
pubmed: 28272130
Yonsei Med J. 2009 Oct 31;50(5):650-5
pubmed: 19881968
Biol Psychiatry. 2003 Dec 15;54(12):1465-8
pubmed: 14675812
Surgery. 2015 Apr;157(4):752-63
pubmed: 25794627
Cogn Psychol. 2000 Aug;41(1):49-100
pubmed: 10945922
JAMA Psychiatry. 2016 Aug 1;73(8):815-825
pubmed: 27276220
Child Neuropsychol. 2008 May;14(3):211-26
pubmed: 17852127
J Exp Psychol. 1958 Apr;55(4):352-8
pubmed: 13539317
J Child Adolesc Psychopharmacol. 2007 Aug;17(4):421-32
pubmed: 17822338
Lancet Psychiatry. 2018 Sep;5(9):727-738
pubmed: 30097390
J Child Adolesc Psychopharmacol. 2009 Aug;19(4):461-5
pubmed: 19702499
J Child Psychol Psychiatry. 2007 Sep;48(9):899-913
pubmed: 17714375
J Atten Disord. 2002;6 Suppl 1:S31-43
pubmed: 12685517
J Abnorm Child Psychol. 2009 Aug;37(6):805-16
pubmed: 19291387
J Abnorm Child Psychol. 2001 Jun;29(3):215-28
pubmed: 11411784
Exp Clin Psychopharmacol. 2021 Aug;29(4):302-307
pubmed: 32297786
J Am Acad Child Adolesc Psychiatry. 2004 Mar;43(3):260-8
pubmed: 15076258
J Atten Disord. 2017 Dec;21(14):1151-1160
pubmed: 25122732
Nat Rev Dis Primers. 2015 Aug 06;1:15020
pubmed: 27189265
Res Dev Disabil. 2013 Oct;34(10):3104-11
pubmed: 23886755
J Abnorm Child Psychol. 2017 Feb;45(2):261-272
pubmed: 27395390